Consultation on Multi-Stakeholder Platform for improving EU Clinical Trials
Recommendation
18-20 November 2025
Heidelberg, Germany
GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing
Register now for ECA's GMP Newsletter
The EMA, together with the HMAs and the European Commission, is gradually implementing the priorities of its joint Accelerating Clinical Trials (ACT) initiative. Most recently, the European Commission published supplementary recommendations on "Decentralized Clinical Trials".
Concept Paper and Press Release
One of the ACT initiative's high-priority projects is a multi-stakeholder platform to support discussions in the clinical research landscape, facilitate the advancement of clinical trial methods and approaches, and help identify areas for progress and practical solutions to enable and drive change. A concept paper outlining the proposal for the creation of the platform has been published together with a press release inviting all stakeholders and the public to comment by 3 March 2023. Comments can be submitted directly online via a web form. The form also asks whether the respective stakeholder organisation is interested in participating in this platform.
Related GMP News
03.04.2025Update on the ICH M11 CeSHArP Technical Specification
03.04.2025EU Map to Clinical Trials
03.04.2025EMA Concept Paper on Model Informed Drug Development
20.03.2025End of the Transition Period for Clinical Trials
11.02.2025Final ICH E6(R3) Guideline on GCP released
11.02.2025FDA issues Draft Guidance on Handling Protocol Deviations in Clinical Trials